PDCD1 and neoplasm: Furthermore, low RNA expression levels of PD1 were reflected in decreased protein levels (Fig. 6H) in DCZ0415‐treated tumours suggesting that DCZ0415 treatment could be activating an antitumour immune response by targeting these two immune checkpoints and leading to less tumour growth in this immunocompetent model.